HOUSTON--(BUSINESS WIRE)--Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce that Dr Randall K. Johnson has agreed to join the Scientific Advisory Board of the company joining a growing number of illustrious oncologists and cancer drug developers. Dr Johnson began his career as section Head of the Experimental Chemotherapy at the National Cancer Institute. Most of his accomplishments occurred over more than twenty years at Glaxo SmithKline where he held various senior positions in oncology culminating in Oncology Group Director. Among the many accomplishments during his tenure was the development of Topotecan which continues to be a major drug used in cancer therapy today. For the past five years Dr Johnson has consulted for numerous drug and biotech companies and is a member of many Scientific Advisory Boards and clinical advisory Boards for oncology based companies.
